董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel M. Schmitt | 男 | President, Chief Executive Officer and Director | 62 | 216.65万美元 | 87.66 | 2024-03-31 |
| Aaron G.L. Fletcher | 男 | Chairperson and Director | 43 | 18.20万美元 | 1029.83 | 2024-03-31 |
| Les Kreis, Jr. | 男 | Director | 52 | 2.33万美元 | 未持股 | 2024-03-31 |
| Todd Thomson | 男 | Director | 63 | 未披露 | 未持股 | 2024-03-31 |
| Dan Zabrowski | 男 | Director | 64 | 16.00万美元 | 未持股 | 2024-03-31 |
| Jason Keyes | 男 | Director | 53 | 16.30万美元 | 2.50 | 2024-03-31 |
| Roger Sawhney | 男 | Director | 54 | 15.95万美元 | 2.50 | 2024-03-31 |
| Amy Ronneberg | 女 | Director | 50 | 15.95万美元 | 2.50 | 2024-03-31 |
| Todd Thomson | 男 | Director | 64 | 14.80万美元 | 242.88 | 2024-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew P. Mazar | 男 | Chief Operating Officer | 62 | 141.96万美元 | 21.18 | 2024-03-31 |
| Daniel M. Schmitt | 男 | President, Chief Executive Officer and Director | 62 | 216.65万美元 | 87.66 | 2024-03-31 |
| Andrew P. Mazar | 男 | Chief Operating Officer | 62 | 未披露 | 未持股 | 2024-03-31 |
| Paul Lytle | 男 | Chief Financial Officer | 56 | 100.64万美元 | 14.43 | 2024-03-31 |
董事简历
中英对照 | 中文 | 英文- Daniel M. Schmitt
-
Daniel M. Schmitt，自2015年3月起担任Actuate Therapeutics，Inc.首席执行官兼总裁，自2015年4月起担任Actuate Therapeutics，Inc.董事。他此前曾于2009年至2014年担任临床阶段公司Genus Oncology LLC的首席运营官。在此之前，他曾于2004年至2009年担任制药公司Immtech Pharmaceuticals，Inc.的许可和商业开发高级副总裁；于2001年至2004年担任基因组技术公司First Genetic Trust的学术和政府机构市场总经理；此前曾在制药公司G.D. Searle Inc.、制药公司ILEX Oncology，Inc.、制药公司Fujisawa USA，Inc.和制药公司Burroughs Wellcome Co.任职。Schmitt先生还曾于1984年担任国家癌症研究基金会附属研究职位，并于1987年至1988年担任北卡罗来纳大学医学院附属研究职位。他还曾于2014年担任西北大学驻校企业家，并于2011年至2014年担任芝加哥大学和伊利诺伊大学—芝加哥分校的外部专家顾问。施密特先生也是芝加哥创新导师的创始成员。他获得了西弗吉尼亚大学理论数学专业的MBA和化学学士学位。Schmitt先生由于其制药和生物技术经验，包括其在运营管理、新产品开发和业务发展方面的经验，完全有资格担任董事。
Daniel M. Schmitt,has served as Actuate Therapeutics, Inc. Chief Executive Officer and President since March 2015 and Actuate Therapeutics, Inc. director since April 2015. He previously served as Chief Operating Officer of Genus Oncology LLC, a clinical stage company, from 2009 to 2014. Prior to that, he served as Senior Vice President, Licensing and Commercial Development of Immtech Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2009; General Manager, Academic and Government Institution Markets of First Genetic Trust, a genomic technology company, from 2001 to 2004; and previously held positions with G.D. Searle Inc., a pharmaceutical company, ILEX Oncology, Inc., a pharmaceutical company, Fujisawa USA, Inc., a pharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company. Mr. Schmitt has also held research positions affiliated with the National Foundation for Cancer Research in 1984 and the University of North Carolina School of Medicine from 1987 to 1988. He also served as an Entrepreneur-In-Residence at Northwestern University in 2014 and as an external expert consultant for both the University of Chicago and the University of Illinois—Chicago from 2011 to 2014. Mr. Schmitt is also a founding member of Chicago Innovation Mentors. He earned his MBA and a BS in Chemistry with a concentration in Theoretical Mathematics from West Virginia University. - Daniel M. Schmitt，自2015年3月起担任Actuate Therapeutics，Inc.首席执行官兼总裁，自2015年4月起担任Actuate Therapeutics，Inc.董事。他此前曾于2009年至2014年担任临床阶段公司Genus Oncology LLC的首席运营官。在此之前，他曾于2004年至2009年担任制药公司Immtech Pharmaceuticals，Inc.的许可和商业开发高级副总裁；于2001年至2004年担任基因组技术公司First Genetic Trust的学术和政府机构市场总经理；此前曾在制药公司G.D. Searle Inc.、制药公司ILEX Oncology，Inc.、制药公司Fujisawa USA，Inc.和制药公司Burroughs Wellcome Co.任职。Schmitt先生还曾于1984年担任国家癌症研究基金会附属研究职位，并于1987年至1988年担任北卡罗来纳大学医学院附属研究职位。他还曾于2014年担任西北大学驻校企业家，并于2011年至2014年担任芝加哥大学和伊利诺伊大学—芝加哥分校的外部专家顾问。施密特先生也是芝加哥创新导师的创始成员。他获得了西弗吉尼亚大学理论数学专业的MBA和化学学士学位。Schmitt先生由于其制药和生物技术经验，包括其在运营管理、新产品开发和业务发展方面的经验，完全有资格担任董事。
- Daniel M. Schmitt,has served as Actuate Therapeutics, Inc. Chief Executive Officer and President since March 2015 and Actuate Therapeutics, Inc. director since April 2015. He previously served as Chief Operating Officer of Genus Oncology LLC, a clinical stage company, from 2009 to 2014. Prior to that, he served as Senior Vice President, Licensing and Commercial Development of Immtech Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2009; General Manager, Academic and Government Institution Markets of First Genetic Trust, a genomic technology company, from 2001 to 2004; and previously held positions with G.D. Searle Inc., a pharmaceutical company, ILEX Oncology, Inc., a pharmaceutical company, Fujisawa USA, Inc., a pharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company. Mr. Schmitt has also held research positions affiliated with the National Foundation for Cancer Research in 1984 and the University of North Carolina School of Medicine from 1987 to 1988. He also served as an Entrepreneur-In-Residence at Northwestern University in 2014 and as an external expert consultant for both the University of Chicago and the University of Illinois—Chicago from 2011 to 2014. Mr. Schmitt is also a founding member of Chicago Innovation Mentors. He earned his MBA and a BS in Chemistry with a concentration in Theoretical Mathematics from West Virginia University.
- Aaron G.L. Fletcher
-
Aaron G.L. Fletcher，自2015年4月起担任Actuate Therapeutics，Inc.董事。Fletcher博士是创始人，自2012年起担任金融服务公司BiOS Research的总裁。Fletcher博士还在生物技术和医疗保健股权行业担任了超过10年的独立顾问，并自2008年起担任达拉斯浸会大学的客座教授，教授生物化学、生物伦理学和细胞生物学。Fletcher博士自2015年7月起担任公共神经科学公司Cognition Therapeutics, Inc.的董事会成员和薪酬委员会成员。此前，他曾担任上市生物制药公司TFF Pharmaceuticals，Inc.的董事会成员以及薪酬委员会和提名与治理委员会成员，于2018年3月至2023年11月，担任上市生物制药公司Cue生物制药的董事会成员以及薪酬委员会和定价委员会成员，于2019年10月至2023年10月，担任生物制药公司Lung Therapeutics，Inc.的董事会和薪酬委员会成员，于2014年8月至2023年10月，担任董事会成员以及AbiliTech Medical的薪酬委员会成员，医疗设备制造商Inc.于2016年11月至2023年1月担任董事会成员，并于2019年8月至2021年12月担任SWK Holdings公司的董事会成员和审计委员会成员，该公司是一家专注于全球医疗保健的公共财务公司。Fletcher博士在科罗拉多州立大学获得生物化学博士学位。Fletcher博士完全有资格担任董事，因为他在医疗保健行业，特别是在生物技术和医疗技术子行业拥有丰富的经验。
Aaron G.L. Fletcher,has served as Actuate Therapeutics, Inc. director since April 2015. Dr. Fletcher is the Founder and has served as the President of Bios Research, a financial services firm, since 2012. Dr. Fletcher has also served as an independent consultant in the biotechnology and healthcare equity industry for over 10 years, and a visiting professor at Dallas Baptist University since 2008, where he teaches Biochemistry, Bioethics and Cell Biology. Dr. Fletcher has served on the board of directors and as a member of the compensation committee of Cognition Therapeutics, Inc., a public neuroscience company, since July 2015. Previously, he served on the board of directors and as a member of the compensation committee and nominating and governance committee of TFF Pharmaceuticals, Inc., a public biopharmaceutical company, from March 2018 to November 2023, the board of directors and as a member of the compensation committee and pricing committee of Cue Biopharma, a public biopharmaceutical company, from October 2019 to October 2023, the board of directors and compensation committee of Lung Therapeutics, Inc., a biopharmaceutical company, from August 2014 to October 2023, the board of directors and as a member of the compensation committee of AbiliTech Medical, Inc., a medical equipment manufacturer, from November 2016 to January 2023, and the board of directors and as a member of the audit committee of SWK Holdings Corporation, a public finance company focused on global healthcare, from August 2019 to December 2021. Dr. Fletcher earned his PhD in Biochemistry from Colorado State University. - Aaron G.L. Fletcher，自2015年4月起担任Actuate Therapeutics，Inc.董事。Fletcher博士是创始人，自2012年起担任金融服务公司BiOS Research的总裁。Fletcher博士还在生物技术和医疗保健股权行业担任了超过10年的独立顾问，并自2008年起担任达拉斯浸会大学的客座教授，教授生物化学、生物伦理学和细胞生物学。Fletcher博士自2015年7月起担任公共神经科学公司Cognition Therapeutics, Inc.的董事会成员和薪酬委员会成员。此前，他曾担任上市生物制药公司TFF Pharmaceuticals，Inc.的董事会成员以及薪酬委员会和提名与治理委员会成员，于2018年3月至2023年11月，担任上市生物制药公司Cue生物制药的董事会成员以及薪酬委员会和定价委员会成员，于2019年10月至2023年10月，担任生物制药公司Lung Therapeutics，Inc.的董事会和薪酬委员会成员，于2014年8月至2023年10月，担任董事会成员以及AbiliTech Medical的薪酬委员会成员，医疗设备制造商Inc.于2016年11月至2023年1月担任董事会成员，并于2019年8月至2021年12月担任SWK Holdings公司的董事会成员和审计委员会成员，该公司是一家专注于全球医疗保健的公共财务公司。Fletcher博士在科罗拉多州立大学获得生物化学博士学位。Fletcher博士完全有资格担任董事，因为他在医疗保健行业，特别是在生物技术和医疗技术子行业拥有丰富的经验。
- Aaron G.L. Fletcher,has served as Actuate Therapeutics, Inc. director since April 2015. Dr. Fletcher is the Founder and has served as the President of Bios Research, a financial services firm, since 2012. Dr. Fletcher has also served as an independent consultant in the biotechnology and healthcare equity industry for over 10 years, and a visiting professor at Dallas Baptist University since 2008, where he teaches Biochemistry, Bioethics and Cell Biology. Dr. Fletcher has served on the board of directors and as a member of the compensation committee of Cognition Therapeutics, Inc., a public neuroscience company, since July 2015. Previously, he served on the board of directors and as a member of the compensation committee and nominating and governance committee of TFF Pharmaceuticals, Inc., a public biopharmaceutical company, from March 2018 to November 2023, the board of directors and as a member of the compensation committee and pricing committee of Cue Biopharma, a public biopharmaceutical company, from October 2019 to October 2023, the board of directors and compensation committee of Lung Therapeutics, Inc., a biopharmaceutical company, from August 2014 to October 2023, the board of directors and as a member of the compensation committee of AbiliTech Medical, Inc., a medical equipment manufacturer, from November 2016 to January 2023, and the board of directors and as a member of the audit committee of SWK Holdings Corporation, a public finance company focused on global healthcare, from August 2019 to December 2021. Dr. Fletcher earned his PhD in Biochemistry from Colorado State University.
- Les Kreis, Jr.
-
Les Kreis，Jr.自2015年3月起担任Actuate Therapeutics，Inc.董事，其任期将在此次发行结束时结束。自2008年以来，Kreis先生一直担任单一家族办公室Steelhead Capital Management的管理负责人。他还是联合创始人，自2013年起担任专注于早期生物技术投资的风险投资公司Bios Partners的管理合伙人。自2012年以来，Kreis先生一直担任天使投资网络Cowtown Angels的创始成员。此前，Kreis先生于1994年至2005年担任私营多策略全球对冲基金HBK Investments的副总裁，并于2019年11月至2022年6月担任上市生物技术公司Lantern Pharma Inc.的董事会成员。Kreis先生于1994年获得得克萨斯基督教大学金融学学士学位。
Les Kreis, Jr.,has served as Actuate Therapeutics, Inc. director since March 2015 and his term will end upon the closing of this offering. Mr. Kreis has served as the Managing Principal of Steelhead Capital Management, a single-family office, since 2008. He is also a Co-Founder and has served as the Managing Partner of Bios Partners, a venture capital firm focused on early-stage biotechnology investments, since 2013. Mr. Kreis has served as a founding member of Cowtown Angels, an angel investment network, since 2012. Previously, Mr. Kreis was a Vice President of HBK Investments, a private multi-strategy global hedge fund, from 1994 to 2005, and served on the board of directors of Lantern Pharma Inc., a public biotechnology company, from November 2019 to June 2022. Mr. Kreis earned a BBA in Finance from Texas Christian University in 1994. - Les Kreis，Jr.自2015年3月起担任Actuate Therapeutics，Inc.董事，其任期将在此次发行结束时结束。自2008年以来，Kreis先生一直担任单一家族办公室Steelhead Capital Management的管理负责人。他还是联合创始人，自2013年起担任专注于早期生物技术投资的风险投资公司Bios Partners的管理合伙人。自2012年以来，Kreis先生一直担任天使投资网络Cowtown Angels的创始成员。此前，Kreis先生于1994年至2005年担任私营多策略全球对冲基金HBK Investments的副总裁，并于2019年11月至2022年6月担任上市生物技术公司Lantern Pharma Inc.的董事会成员。Kreis先生于1994年获得得克萨斯基督教大学金融学学士学位。
- Les Kreis, Jr.,has served as Actuate Therapeutics, Inc. director since March 2015 and his term will end upon the closing of this offering. Mr. Kreis has served as the Managing Principal of Steelhead Capital Management, a single-family office, since 2008. He is also a Co-Founder and has served as the Managing Partner of Bios Partners, a venture capital firm focused on early-stage biotechnology investments, since 2013. Mr. Kreis has served as a founding member of Cowtown Angels, an angel investment network, since 2012. Previously, Mr. Kreis was a Vice President of HBK Investments, a private multi-strategy global hedge fund, from 1994 to 2005, and served on the board of directors of Lantern Pharma Inc., a public biotechnology company, from November 2019 to June 2022. Mr. Kreis earned a BBA in Finance from Texas Christian University in 1994.
- Todd Thomson
-
Todd Thomson，自2022年9月起担任Actuate Therapeutics，Inc.董事。Thomson先生自2019年8月起担任风险投资公司Kairos Ventures的首席运营和财务官。此前，曾于2010年11月至2019年8月共同创立投资与技术平台Dynasty Financial Partners并担任董事长，现任董事会成员。在此之前，Thomson先生曾担任花旗集团财富管理部门的首席执行官，此前曾于1998年至2007年担任投资银行和金融服务公司Citigroup Inc.的首席财务官。Thomson先生曾担任公共技术公司Sivers Semiconductors的董事会成员和审计委员会成员，自2022年1月起担任公共电池制造商Dragonfly Energy Holdings Corp.的董事会成员，于2021年8月至2022年10月担任公共网络安全公司CYREN Ltd.的董事会成员，于2011年11月至2021年7月担任银行控股公司Cordia Bancorp Inc.的董事会成员，于2010年至2016年5月，和董事会，并作为戴维森学院和世界资源研究所捐赠基金投资委员会成员。他在沃顿商学院获得了卓越的金融和战略MBA学位，并在戴维森学院获得了经济学学士学位。Thomson先生由于其丰富的投资经验和多年的行政领导、财务领导以及在并购和业务战略方面的经验，完全有资格担任董事。
Todd Thomson,has served as Actuate Therapeutics, Inc. director since September 2022. Mr. Thomson has served as the Chief Operating and Financial Officer of Kairos Ventures, a venture capital firm, since August 2019. Previously, he co-founded and served as Chairman of Dynasty Financial Partners, an investment and technology platform, from November 2010 to August 2019, and currently serves on the board of directors. Prior to that, Mr. Thomson served as CEO of the Wealth Management Division of Citigroup and previously Chief Financial Officer of Citigroup Inc., an investment bank and financial services corporation, from 1998 to 2007. Mr. Thomson has served on the board of directors and as a member of the audit committee of Sivers Semiconductors, a public technology company, since January 2022, the board of directors of Dragonfly Energy Holdings Corp., a public battery manufacturer, from August 2021 to October 2022, the board of directors of Cyren Ltd., a public cybersecurity company, from November 2011 to July 2021, the board of directors of Cordia Bancorp Inc., a bank holding company, from 2010 to May 2016, and the board of directors and as a member of the Investment Committee for the Davidson College and World Resources Institute Endowments. He earned his MBA with Distinction in Finance and Strategy from the Wharton School of Business and his BA in Economics from Davidson College. - Todd Thomson，自2022年9月起担任Actuate Therapeutics，Inc.董事。Thomson先生自2019年8月起担任风险投资公司Kairos Ventures的首席运营和财务官。此前，曾于2010年11月至2019年8月共同创立投资与技术平台Dynasty Financial Partners并担任董事长，现任董事会成员。在此之前，Thomson先生曾担任花旗集团财富管理部门的首席执行官，此前曾于1998年至2007年担任投资银行和金融服务公司Citigroup Inc.的首席财务官。Thomson先生曾担任公共技术公司Sivers Semiconductors的董事会成员和审计委员会成员，自2022年1月起担任公共电池制造商Dragonfly Energy Holdings Corp.的董事会成员，于2021年8月至2022年10月担任公共网络安全公司CYREN Ltd.的董事会成员，于2011年11月至2021年7月担任银行控股公司Cordia Bancorp Inc.的董事会成员，于2010年至2016年5月，和董事会，并作为戴维森学院和世界资源研究所捐赠基金投资委员会成员。他在沃顿商学院获得了卓越的金融和战略MBA学位，并在戴维森学院获得了经济学学士学位。Thomson先生由于其丰富的投资经验和多年的行政领导、财务领导以及在并购和业务战略方面的经验，完全有资格担任董事。
- Todd Thomson,has served as Actuate Therapeutics, Inc. director since September 2022. Mr. Thomson has served as the Chief Operating and Financial Officer of Kairos Ventures, a venture capital firm, since August 2019. Previously, he co-founded and served as Chairman of Dynasty Financial Partners, an investment and technology platform, from November 2010 to August 2019, and currently serves on the board of directors. Prior to that, Mr. Thomson served as CEO of the Wealth Management Division of Citigroup and previously Chief Financial Officer of Citigroup Inc., an investment bank and financial services corporation, from 1998 to 2007. Mr. Thomson has served on the board of directors and as a member of the audit committee of Sivers Semiconductors, a public technology company, since January 2022, the board of directors of Dragonfly Energy Holdings Corp., a public battery manufacturer, from August 2021 to October 2022, the board of directors of Cyren Ltd., a public cybersecurity company, from November 2011 to July 2021, the board of directors of Cordia Bancorp Inc., a bank holding company, from 2010 to May 2016, and the board of directors and as a member of the Investment Committee for the Davidson College and World Resources Institute Endowments. He earned his MBA with Distinction in Finance and Strategy from the Wharton School of Business and his BA in Economics from Davidson College.
- Dan Zabrowski
-
Dan Zabrowski，自2021年3月起担任Actuate Therapeutics，Inc.董事。Zabrowski博士自2016年7月起担任私人投资公司德诚资本的风险合伙人。在此之前，Zabrowski博士曾于1994年至2016年在医疗保健公司罗氏担任多个职务，包括监管事务全球主管、开发运营全球主管、罗氏制药合作全球主管、Ventana医疗系统总裁和罗氏测序部门总裁。Zabrowski博士此前还曾在Syntex、制药公司Fujisawa（现为Astellas）和制药公司G.D. Searle，LLC任职，并在伊利诺伊大学芝加哥分校药学院担任兼职助理教授。他还于2021年2月至2023年8月期间担任上市生物制药公司Apexigen, Inc.的董事会成员，包括于2020年1月至2022年6月期间担任其薪酬委员会主席和审计委员会成员，上市生物制药公司BeyondSpring Inc.，包括担任其薪酬委员会成员，私营生物技术公司Nimble Therapeutics，Inc.自2019年起，私营生物技术公司Ariagen，Inc.自2018年起，私营生物技术公司Endogena Therapeutics，Inc.自2018年起，私营生物技术公司AccuraGen，Inc.自2013年起，并自2018年起担任私营生物技术公司Encodia，Inc.的董事会观察员。Zabrowski博士在布卢明顿的印第安纳大学获得有机化学博士学位，并在圣路易斯大学获得化学学士学位。Zabrowski博士非常有资格担任董事，因为他在生物技术和生物制药行业的各种公共和私人董事会拥有丰富的经验。
Dan Zabrowski,has served as Actuate Therapeutics, Inc. director since March 2021. Dr. Zabrowski has served as a Venture Partner of Decheng Capital, a private investment firm, since July 2016. Prior to that, Dr. Zabrowski served in a number of roles for Roche, a healthcare company, from 1994 to 2016, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. Dr. Zabrowski also previously held positions with Syntex, Fujisawa (now Astellas), a pharmaceutical company, and G.D. Searle, LLC, a pharmaceutical company, and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois—Chicago. He also served on the board of directors of Apexigen, Inc., a public biopharmaceutical company, from February 2021 to August 2023, including serving as Chairman of its compensation committee and member of its audit committee, BeyondSpring Inc., a public biopharmaceutical company, from January 2020 to June 2022, including serving as a member of its compensation committee, Nimble Therapeutics, Inc., a private biotechnology company, since 2019, Ariagen, Inc., a private biotechnology company, since 2018, Endogena Therapeutics, Inc., a private biotechnology company, since 2018, and AccuraGen, Inc., a private biotechnology company, since 2013, and also as a board observer for Encodia, Inc., a private biotechnology company, since 2018. Dr. Zabrowski earned his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University. - Dan Zabrowski，自2021年3月起担任Actuate Therapeutics，Inc.董事。Zabrowski博士自2016年7月起担任私人投资公司德诚资本的风险合伙人。在此之前，Zabrowski博士曾于1994年至2016年在医疗保健公司罗氏担任多个职务，包括监管事务全球主管、开发运营全球主管、罗氏制药合作全球主管、Ventana医疗系统总裁和罗氏测序部门总裁。Zabrowski博士此前还曾在Syntex、制药公司Fujisawa（现为Astellas）和制药公司G.D. Searle，LLC任职，并在伊利诺伊大学芝加哥分校药学院担任兼职助理教授。他还于2021年2月至2023年8月期间担任上市生物制药公司Apexigen, Inc.的董事会成员，包括于2020年1月至2022年6月期间担任其薪酬委员会主席和审计委员会成员，上市生物制药公司BeyondSpring Inc.，包括担任其薪酬委员会成员，私营生物技术公司Nimble Therapeutics，Inc.自2019年起，私营生物技术公司Ariagen，Inc.自2018年起，私营生物技术公司Endogena Therapeutics，Inc.自2018年起，私营生物技术公司AccuraGen，Inc.自2013年起，并自2018年起担任私营生物技术公司Encodia，Inc.的董事会观察员。Zabrowski博士在布卢明顿的印第安纳大学获得有机化学博士学位，并在圣路易斯大学获得化学学士学位。Zabrowski博士非常有资格担任董事，因为他在生物技术和生物制药行业的各种公共和私人董事会拥有丰富的经验。
- Dan Zabrowski,has served as Actuate Therapeutics, Inc. director since March 2021. Dr. Zabrowski has served as a Venture Partner of Decheng Capital, a private investment firm, since July 2016. Prior to that, Dr. Zabrowski served in a number of roles for Roche, a healthcare company, from 1994 to 2016, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. Dr. Zabrowski also previously held positions with Syntex, Fujisawa (now Astellas), a pharmaceutical company, and G.D. Searle, LLC, a pharmaceutical company, and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois—Chicago. He also served on the board of directors of Apexigen, Inc., a public biopharmaceutical company, from February 2021 to August 2023, including serving as Chairman of its compensation committee and member of its audit committee, BeyondSpring Inc., a public biopharmaceutical company, from January 2020 to June 2022, including serving as a member of its compensation committee, Nimble Therapeutics, Inc., a private biotechnology company, since 2019, Ariagen, Inc., a private biotechnology company, since 2018, Endogena Therapeutics, Inc., a private biotechnology company, since 2018, and AccuraGen, Inc., a private biotechnology company, since 2013, and also as a board observer for Encodia, Inc., a private biotechnology company, since 2018. Dr. Zabrowski earned his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.
- Jason Keyes
-
Jason Keyes自2025年5月起担任Blossomhill Therapeutics，Inc.执行副总裁兼首席财务官。在加入BlossomHill之前，Keyes先生于2018年3月至2025年4月期间担任Equillium，Inc.的首席财务官。从2013年1月到2018年2月，Keyes先生在Orexigen Therapeutics, Inc.（Orexigen）这一上市制药公司担任各种职责不断增加的职务，最近担任执行副总裁兼首席财务官。从2007年8月到2013年1月，Keyes先生在Amylin Pharmaceuticals, Inc.担任过多个财务领导职务，包括担任财务高级总监，该公司于2012年被百时美施贵宝收购。在其职业生涯的早期，凯斯先生还曾在安进公司和百特医疗保健公司担任财务和公司战略方面的领导职务。自2024年8月起，Keyes先生担任Actuate Therapeutics，Inc.的董事会成员和审计委员会主席。自2020年2月至2023年3月，Keyes先生还担任Sesen Bio, Inc.的董事会成员以及审计委员会主席和薪酬委员会成员。Keyes先生获得斯坦福大学土木工程学士和硕士学位，以及加州大学洛杉矶分校安德森学院的MBA学位。
Jason Keyes has served as Blossomhill Therapeutics, Inc.'s Executive Vice President and Chief Financial Officer since May 2025. Prior to joining BlossomHill, Mr. Keyes served as the Chief Financial Officer of Equillium, Inc. from March 2018 through April 2025. From January 2013 through February 2018, Mr. Keyes served in various roles of increasing responsibility at Orexigen Therapeutics, Inc. (Orexigen), a publicly held pharmaceutical company, serving most recently as Executive Vice President and Chief Financial Officer. From August 2007 through January 2013, Mr. Keyes served in various financial leadership roles, including as Senior Director of Finance, at Amylin Pharmaceuticals, Inc., which was acquired by Bristol Myers Squibb in 2012. Earlier in his career, Mr. Keyes also held leadership positions in finance and corporate strategy at Amgen Inc. and at Baxter HealthcareCorporation. Since August 2024, Mr. Keyes has served on the board of directors and as chair of the audit committee of Actuate Therapeutics, Inc. From February 2020 to March 2023, Mr. Keyes also served on the board of directors and as chair of the audit committee and member of the compensation committee of Sesen Bio, Inc. Mr. Keyes received his B.S. and M.S. in civil engineering from Stanford University and his MBA from the Anderson School at the University of California, Los Angeles. - Jason Keyes自2025年5月起担任Blossomhill Therapeutics，Inc.执行副总裁兼首席财务官。在加入BlossomHill之前，Keyes先生于2018年3月至2025年4月期间担任Equillium，Inc.的首席财务官。从2013年1月到2018年2月，Keyes先生在Orexigen Therapeutics, Inc.（Orexigen）这一上市制药公司担任各种职责不断增加的职务，最近担任执行副总裁兼首席财务官。从2007年8月到2013年1月，Keyes先生在Amylin Pharmaceuticals, Inc.担任过多个财务领导职务，包括担任财务高级总监，该公司于2012年被百时美施贵宝收购。在其职业生涯的早期，凯斯先生还曾在安进公司和百特医疗保健公司担任财务和公司战略方面的领导职务。自2024年8月起，Keyes先生担任Actuate Therapeutics，Inc.的董事会成员和审计委员会主席。自2020年2月至2023年3月，Keyes先生还担任Sesen Bio, Inc.的董事会成员以及审计委员会主席和薪酬委员会成员。Keyes先生获得斯坦福大学土木工程学士和硕士学位，以及加州大学洛杉矶分校安德森学院的MBA学位。
- Jason Keyes has served as Blossomhill Therapeutics, Inc.'s Executive Vice President and Chief Financial Officer since May 2025. Prior to joining BlossomHill, Mr. Keyes served as the Chief Financial Officer of Equillium, Inc. from March 2018 through April 2025. From January 2013 through February 2018, Mr. Keyes served in various roles of increasing responsibility at Orexigen Therapeutics, Inc. (Orexigen), a publicly held pharmaceutical company, serving most recently as Executive Vice President and Chief Financial Officer. From August 2007 through January 2013, Mr. Keyes served in various financial leadership roles, including as Senior Director of Finance, at Amylin Pharmaceuticals, Inc., which was acquired by Bristol Myers Squibb in 2012. Earlier in his career, Mr. Keyes also held leadership positions in finance and corporate strategy at Amgen Inc. and at Baxter HealthcareCorporation. Since August 2024, Mr. Keyes has served on the board of directors and as chair of the audit committee of Actuate Therapeutics, Inc. From February 2020 to March 2023, Mr. Keyes also served on the board of directors and as chair of the audit committee and member of the compensation committee of Sesen Bio, Inc. Mr. Keyes received his B.S. and M.S. in civil engineering from Stanford University and his MBA from the Anderson School at the University of California, Los Angeles.
- Roger Sawhney
-
Roger Sawhney于2024年8月至2025年7月期间担任Adlai Nortye Ltd.的董事，随后从董事重新指定为独立董事。他在生命科学行业拥有近三十年的财务和战略专长。Sawhney博士目前担任LB Pharmaceuticals的首席财务官，LB Pharmaceuticals是一家专注于神经心理的公司，总部位于纽约市。2022年9月至2023年12月，Sawhney博士担任Garuda Therapeutics，Inc.的首席财务官。2020年3月至2022年5月，Sawhney博士担任Omega Therapeutics, Inc.（一家基于mRNA的精准基因调节疗法的先驱）的首席财务官，并于2022年5月至2022年9月担任Omega的首席商务官。2018年9月至2020年8月，Sawhney博士在全球投资公司KKR & Co. Inc.任职，担任其美洲医疗保健投资平台的董事，他的工作重点是医疗保健领域的私人和成长型股权投资。2009年7月至2012年8月，Sawhney博士担任诺华公司高级副总裁兼全球企业战略主管，并于2017年2月至2018年2月担任Outcome Health公司战略和业务发展高级副总裁。Sawhney博士还曾于2012年8月至2017年2月担任贝恩公司合伙人，并于1996年至2009年担任波士顿咨询公司合伙人，负责管理生命科学、医疗技术和数字健康领域的众多客户业务。Sawhney博士拥有哈佛医学院的医学博士学位和斯坦福大学的经济学学士学位。
Roger Sawhney served as Adlai Nortye Ltd.'s director from August 2024 to July 2025 and subsequently re designation from a director to an independent. He has nearly thirty years of financial and strategic expertise across the life sciences industry. Dr. Sawhney currently serves as the Chief Financial Officer of LB Pharmaceuticals, a neuro psych focused Company, based in New York City. From September 2022 to December 2023, Dr. Sawhney served as the Chief Financial Officer of Garuda Therapeutics, Inc. From March 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc., a pioneer in mRNA based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022. From September 2018 to August 2020, Dr. Sawhney served at KKR & Co. Inc., a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investments across private and growth equity in the healthcare sector. From July 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney also served as Partner with Bain & Company from August 2012 to February 2017 and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med tech and digital health sectors. Dr. Sawhney holds an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University. - Roger Sawhney于2024年8月至2025年7月期间担任Adlai Nortye Ltd.的董事，随后从董事重新指定为独立董事。他在生命科学行业拥有近三十年的财务和战略专长。Sawhney博士目前担任LB Pharmaceuticals的首席财务官，LB Pharmaceuticals是一家专注于神经心理的公司，总部位于纽约市。2022年9月至2023年12月，Sawhney博士担任Garuda Therapeutics，Inc.的首席财务官。2020年3月至2022年5月，Sawhney博士担任Omega Therapeutics, Inc.（一家基于mRNA的精准基因调节疗法的先驱）的首席财务官，并于2022年5月至2022年9月担任Omega的首席商务官。2018年9月至2020年8月，Sawhney博士在全球投资公司KKR & Co. Inc.任职，担任其美洲医疗保健投资平台的董事，他的工作重点是医疗保健领域的私人和成长型股权投资。2009年7月至2012年8月，Sawhney博士担任诺华公司高级副总裁兼全球企业战略主管，并于2017年2月至2018年2月担任Outcome Health公司战略和业务发展高级副总裁。Sawhney博士还曾于2012年8月至2017年2月担任贝恩公司合伙人，并于1996年至2009年担任波士顿咨询公司合伙人，负责管理生命科学、医疗技术和数字健康领域的众多客户业务。Sawhney博士拥有哈佛医学院的医学博士学位和斯坦福大学的经济学学士学位。
- Roger Sawhney served as Adlai Nortye Ltd.'s director from August 2024 to July 2025 and subsequently re designation from a director to an independent. He has nearly thirty years of financial and strategic expertise across the life sciences industry. Dr. Sawhney currently serves as the Chief Financial Officer of LB Pharmaceuticals, a neuro psych focused Company, based in New York City. From September 2022 to December 2023, Dr. Sawhney served as the Chief Financial Officer of Garuda Therapeutics, Inc. From March 2020 to May 2022, Dr. Sawhney served as the Chief Financial Officer of Omega Therapeutics, Inc., a pioneer in mRNA based therapeutics for precision gene modulation, and he served as the Chief Business Officer of Omega from May 2022 to September 2022. From September 2018 to August 2020, Dr. Sawhney served at KKR & Co. Inc., a global investment firm, as Director of its healthcare investment platform in the Americas where his work focused on investments across private and growth equity in the healthcare sector. From July 2009 to August 2012, Dr. Sawhney served as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, as well as Senior Vice President of Corporate Strategy and Business Development for Outcome Health from February 2017 to February 2018. Dr. Sawhney also served as Partner with Bain & Company from August 2012 to February 2017 and the Boston Consulting Group from 1996 to 2009, where he managed numerous client engagements across the life sciences, med tech and digital health sectors. Dr. Sawhney holds an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University.
- Amy Ronneberg
-
Amy Ronneberg，已被任命为Actuate Therapeutics，Inc.董事，自本次发行完成后生效。Ronneberg女士目前自2020年3月起担任促进骨髓移植的非营利组织NMDP（f/k/a Be the Match）的首席执行官，并于2013年7月至2020年3月担任其首席财务官。Ronneberg女士还曾在NMDP内的初创公司NMDP BioTherapies，LLC担任总裁，并于2018年2月至2020年2月担任其参谋长。在此之前，Ronneberg女士曾于2000年至2012年在Capella Education Company（一家公立在线专上教育服务公司）担任多个职务，包括担任首席会计官和运营副总裁。她还曾于1995年至2000年担任专业服务合伙企业安永会计师事务所的审计经理。Ronneberg女士自2020年11月起担任非营利性医疗保健公司Allina Health的董事和财务委员会成员（副主席），此前曾于2018年6月至2023年8月担任临床阶段生物技术公司Magenta Therapeutics, Inc.的董事，于2020年12月至今担任医疗保健行业网络Medical Alley Association的董事和执行委员会成员，于2017年1月至2020年1月担任国际医疗保健组织世界骨髓捐献者协会的执行委员会成员，以及明尼阿波利斯Twin Cities in Motion的董事会主席，非营利性跑步活动组织，2012年1月至2014年1月。Ronneberg女士在明尼苏达州明尼阿波利斯市卡佩拉大学获得工商管理硕士学位，并在威斯康星大学欧克莱尔分校获得会计学学士学位。Ronneberg女士非常有资格担任董事，因为她在生物技术和生物制药行业拥有广泛的金融专业知识和领导能力。
Amy Ronneberg,has been appointed to serve as Actuate Therapeutics, Inc. director, effective upon the completion of this offering. Ms. Ronneberg currently serves as the Chief Executive Officer of NMDP (f/k/a Be The Match), a nonprofit organization that facilitates bone marrow transplantation, since March 2020, and served as its Chief Financial Officer from July 2013 to March 2020. Ms. Ronneberg also served as the President at NMDP BioTherapies, LLC, a start-up company within NMDP, and as its Chief of Staff from February 2018 to February 2020. Prior to that, Ms. Ronneberg served in various roles at Capella Education Company, a public online postsecondary education services company, including as Chief Accounting Officer and Vice President of Operations, from 2000 to 2012. She also served as an Audit Manager of Ernst & Young, a professional services partnership, from 1995 to 2000. Ms. Ronneberg has served as a director and member of the finance committee (Vice Chair) for Allina Health, a nonprofit healthcare company, since November 2020, and previously served as a director of Magenta Therapeutics, Inc., a clinical stage biotechnology company, from June 2018 to August 2023, a director and executive committee member of Medical Alley Association, a healthcare industry network, from December 2020 to present, an executive committee member of the World Marrow Donor Association, an international healthcare organization, from January 2017 to January 2020, and chairman of the board of directors of Twin Cities in Motion, Minneapolis, a nonprofit running event organization, from January 2012 to January 2014. Ms. Ronneberg earned a Master's in Business Administration from Capella University, Minneapolis, Minnesota, and a B.B.A. in Accounting from University of Wisconsin-Eau Claire. - Amy Ronneberg，已被任命为Actuate Therapeutics，Inc.董事，自本次发行完成后生效。Ronneberg女士目前自2020年3月起担任促进骨髓移植的非营利组织NMDP（f/k/a Be the Match）的首席执行官，并于2013年7月至2020年3月担任其首席财务官。Ronneberg女士还曾在NMDP内的初创公司NMDP BioTherapies，LLC担任总裁，并于2018年2月至2020年2月担任其参谋长。在此之前，Ronneberg女士曾于2000年至2012年在Capella Education Company（一家公立在线专上教育服务公司）担任多个职务，包括担任首席会计官和运营副总裁。她还曾于1995年至2000年担任专业服务合伙企业安永会计师事务所的审计经理。Ronneberg女士自2020年11月起担任非营利性医疗保健公司Allina Health的董事和财务委员会成员（副主席），此前曾于2018年6月至2023年8月担任临床阶段生物技术公司Magenta Therapeutics, Inc.的董事，于2020年12月至今担任医疗保健行业网络Medical Alley Association的董事和执行委员会成员，于2017年1月至2020年1月担任国际医疗保健组织世界骨髓捐献者协会的执行委员会成员，以及明尼阿波利斯Twin Cities in Motion的董事会主席，非营利性跑步活动组织，2012年1月至2014年1月。Ronneberg女士在明尼苏达州明尼阿波利斯市卡佩拉大学获得工商管理硕士学位，并在威斯康星大学欧克莱尔分校获得会计学学士学位。Ronneberg女士非常有资格担任董事，因为她在生物技术和生物制药行业拥有广泛的金融专业知识和领导能力。
- Amy Ronneberg,has been appointed to serve as Actuate Therapeutics, Inc. director, effective upon the completion of this offering. Ms. Ronneberg currently serves as the Chief Executive Officer of NMDP (f/k/a Be The Match), a nonprofit organization that facilitates bone marrow transplantation, since March 2020, and served as its Chief Financial Officer from July 2013 to March 2020. Ms. Ronneberg also served as the President at NMDP BioTherapies, LLC, a start-up company within NMDP, and as its Chief of Staff from February 2018 to February 2020. Prior to that, Ms. Ronneberg served in various roles at Capella Education Company, a public online postsecondary education services company, including as Chief Accounting Officer and Vice President of Operations, from 2000 to 2012. She also served as an Audit Manager of Ernst & Young, a professional services partnership, from 1995 to 2000. Ms. Ronneberg has served as a director and member of the finance committee (Vice Chair) for Allina Health, a nonprofit healthcare company, since November 2020, and previously served as a director of Magenta Therapeutics, Inc., a clinical stage biotechnology company, from June 2018 to August 2023, a director and executive committee member of Medical Alley Association, a healthcare industry network, from December 2020 to present, an executive committee member of the World Marrow Donor Association, an international healthcare organization, from January 2017 to January 2020, and chairman of the board of directors of Twin Cities in Motion, Minneapolis, a nonprofit running event organization, from January 2012 to January 2014. Ms. Ronneberg earned a Master's in Business Administration from Capella University, Minneapolis, Minnesota, and a B.B.A. in Accounting from University of Wisconsin-Eau Claire.
- Todd Thomson
-
Todd Thomson，2011年11月他加入董事会。Thomson先生目前是Dynasty金融，一家致力于给独立顾问提供投资和技术平台的公司的董事长。Thomson先生也是Headwaters Capita，一家自营投资业务和战略咨询公司的创始人和CEO。1998年到2007年，Thomson先生曾在花旗集团担任高层管理职位，包括花旗集团的首席财务官，花旗集团的全球财富管理事业部的首席执行官。加入花旗集团之前，Thomson先生在GE Capital，Barents集团，Bank of Virginia和世界资源研究所担任高级职位。Thomson先生也是沃顿商学院领导顾问委员会的主席，戴维森学院的前董事会成员。Thomson先生以优异的成绩拥有沃顿商学院的M.B.A。学位和戴维森大学经济学学士学位。
Todd Thomson is a member of our board of directors. He is currently the chief operating officer and chief financial officer of Kairos Ventures, an early-stage investment firm. He is an accomplished operating executive and entrepreneur, having served as Citigroup chief financial officer for five years and as chief executive officer of Citigroup's nearly $10 billion global wealth management division for more than two years. Mr. Thomson is a leading practitioner on mergers and acquisitions and business strategy, having led the acquisition and strategy efforts for Ciigroup and GE Capital, as well as serving as advisor to Fortune 500 firms while at Bain & Co., Booz Allen Hamilton, and Barents Group. He has extensive investing experience as chief executive officer of Citigroup alternative investments, chairman of the Citigroup pension investment committee, chairman of the dynasty investment committee, and a member of the investment committees for the Davidson College and World Resources Institute endowments. Prior to joining Kairos Ventures, Mr. Thomson served as co-founder and chairman of Dynasty Financial Partners, or Dynasty, a leading investment and technology platform for sophisticated independent advisors. Founded by Mr. Thomson and his colleagues in 2010 Dynasty serves nearly 50 registered investment advisor firms nationally, with $50 billion under management. In addition to serving as chairman, Todd served in several operating roles since Dynasty's founding, including chairing the investment committee, serving as chief investment officer, and designing and leading Dynasty Capital Strategies. Mr. Thomson has also agreed to serve on the board of Chardan NexTech Acquisition Corp., a blank check company, upon the effectiveness of its registration statement. - Todd Thomson，2011年11月他加入董事会。Thomson先生目前是Dynasty金融，一家致力于给独立顾问提供投资和技术平台的公司的董事长。Thomson先生也是Headwaters Capita，一家自营投资业务和战略咨询公司的创始人和CEO。1998年到2007年，Thomson先生曾在花旗集团担任高层管理职位，包括花旗集团的首席财务官，花旗集团的全球财富管理事业部的首席执行官。加入花旗集团之前，Thomson先生在GE Capital，Barents集团，Bank of Virginia和世界资源研究所担任高级职位。Thomson先生也是沃顿商学院领导顾问委员会的主席，戴维森学院的前董事会成员。Thomson先生以优异的成绩拥有沃顿商学院的M.B.A。学位和戴维森大学经济学学士学位。
- Todd Thomson is a member of our board of directors. He is currently the chief operating officer and chief financial officer of Kairos Ventures, an early-stage investment firm. He is an accomplished operating executive and entrepreneur, having served as Citigroup chief financial officer for five years and as chief executive officer of Citigroup's nearly $10 billion global wealth management division for more than two years. Mr. Thomson is a leading practitioner on mergers and acquisitions and business strategy, having led the acquisition and strategy efforts for Ciigroup and GE Capital, as well as serving as advisor to Fortune 500 firms while at Bain & Co., Booz Allen Hamilton, and Barents Group. He has extensive investing experience as chief executive officer of Citigroup alternative investments, chairman of the Citigroup pension investment committee, chairman of the dynasty investment committee, and a member of the investment committees for the Davidson College and World Resources Institute endowments. Prior to joining Kairos Ventures, Mr. Thomson served as co-founder and chairman of Dynasty Financial Partners, or Dynasty, a leading investment and technology platform for sophisticated independent advisors. Founded by Mr. Thomson and his colleagues in 2010 Dynasty serves nearly 50 registered investment advisor firms nationally, with $50 billion under management. In addition to serving as chairman, Todd served in several operating roles since Dynasty's founding, including chairing the investment committee, serving as chief investment officer, and designing and leading Dynasty Capital Strategies. Mr. Thomson has also agreed to serve on the board of Chardan NexTech Acquisition Corp., a blank check company, upon the effectiveness of its registration statement.
高管简历
中英对照 | 中文 | 英文- Andrew P. Mazar
AndrewP.Mazar是我们和我们的前身Monopar Therapeutics，LLC的联合创始人，自2014年12月成立以来一直担任我们的首席科学官和董事会成员。Mazar博士自2017年11月1日起担任研究与开发执行Vice President。他曾创立或共同创立8家初创公司，将新药发现商业化，包括Tactic Pharma公司（原为生物制药公司），在那里他曾任职（2010年以来），在那里他曾收购并开发临床前和临床阶段化合物。Mazar博士在过去五年中创立或建议了几家初创公司，包括Tactic Pharma，Valence Therapeutics（一家生物制药公司），Wilson Therapeutics（一家生物制药公司），Panther Biotechnology（一家生物制药公司），Lung Therapeutics Inc.（一家生物制药公司），Actuate Therapeutics（一家肿瘤生物制药公司），Avidtox（一家生物制药公司）和Tempus（一家生物制药公司）。在2010年加入Tactic Pharma和2009年加入Northwestern University生命过程化学研究所之前，Mazar博士从2000年到2009年担任Attenuon，LLC（圣地亚哥一家生物制药公司）的首席科学官。Mazar博士是国家癌症研究所纳米技术联盟动物模型工作组的前任主席（2011-2015年），并自2011年以来一直是SMART计划的国家心肺血液研究所科学审查委员会（SRB）的成员。Mazar博士目前是西北大学（Northwestern University）临床癌症研究（Clinical Cancer Research）的编辑委员会和Newcures的外部顾问委员会的成员。Mazar博士在伊利诺伊大学医学院（University of Illinois College of Medicine）获得生物化学博士学位。
Andrew P. Mazar,has served as Actuate Therapeutics, Inc. Chief Operating Officer since June 2022, and prior to joining the Company, he served as an independent consultant from January 2022 to June 2022. Previously, Dr. Mazar was the Co-Founder, Chief Scientific Officer and a director of Monopar Therapeutics, Inc., a public clinical-stage biopharmaceutical company, from September 2016 to April 2022. Dr. Mazar is also a founder and managing member of Tactic Pharma, LLC, where he developed WTX-101/ALXN1840, a drug he co-invented for the treatment of Wilson's disease. WTX-101/ALXN1840 was acquired by Alexion Pharmaceuticals for more than $800 million in 2018. Prior to Monopar, Dr. Mazar was a Professor of Pharmacology at the Feinberg School of Medicine at Northwestern University, where he also served as the Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence from September 2009 to September 2016. During his tenure at Northwestern University, Dr, Mazar served as the Co-chair of the Animal Model Working Group for the NCI Nanotechnology Alliance; was a charter member of the Developmental Therapeutics (DT) study section at the NIH Center for Scientific review; and was a member of the editorial board of Clinical Cancer Research where he continues to serve. Prior to that, Dr. Mazar served as the Chief Scientific Officer at Attenuon, LLC, a private clinical-stage biopharmaceutical company, from February 2000 to July 2009. Dr. Mazar earned his BS in Chemistry from the University of Wisconsin, Parkside and his Ph.D. in Biochemistry from the University of Illinois College of Medicine, Chicago, Illinois.- AndrewP.Mazar是我们和我们的前身Monopar Therapeutics，LLC的联合创始人，自2014年12月成立以来一直担任我们的首席科学官和董事会成员。Mazar博士自2017年11月1日起担任研究与开发执行Vice President。他曾创立或共同创立8家初创公司，将新药发现商业化，包括Tactic Pharma公司（原为生物制药公司），在那里他曾任职（2010年以来），在那里他曾收购并开发临床前和临床阶段化合物。Mazar博士在过去五年中创立或建议了几家初创公司，包括Tactic Pharma，Valence Therapeutics（一家生物制药公司），Wilson Therapeutics（一家生物制药公司），Panther Biotechnology（一家生物制药公司），Lung Therapeutics Inc.（一家生物制药公司），Actuate Therapeutics（一家肿瘤生物制药公司），Avidtox（一家生物制药公司）和Tempus（一家生物制药公司）。在2010年加入Tactic Pharma和2009年加入Northwestern University生命过程化学研究所之前，Mazar博士从2000年到2009年担任Attenuon，LLC（圣地亚哥一家生物制药公司）的首席科学官。Mazar博士是国家癌症研究所纳米技术联盟动物模型工作组的前任主席（2011-2015年），并自2011年以来一直是SMART计划的国家心肺血液研究所科学审查委员会（SRB）的成员。Mazar博士目前是西北大学（Northwestern University）临床癌症研究（Clinical Cancer Research）的编辑委员会和Newcures的外部顾问委员会的成员。Mazar博士在伊利诺伊大学医学院（University of Illinois College of Medicine）获得生物化学博士学位。
- Andrew P. Mazar,has served as Actuate Therapeutics, Inc. Chief Operating Officer since June 2022, and prior to joining the Company, he served as an independent consultant from January 2022 to June 2022. Previously, Dr. Mazar was the Co-Founder, Chief Scientific Officer and a director of Monopar Therapeutics, Inc., a public clinical-stage biopharmaceutical company, from September 2016 to April 2022. Dr. Mazar is also a founder and managing member of Tactic Pharma, LLC, where he developed WTX-101/ALXN1840, a drug he co-invented for the treatment of Wilson's disease. WTX-101/ALXN1840 was acquired by Alexion Pharmaceuticals for more than $800 million in 2018. Prior to Monopar, Dr. Mazar was a Professor of Pharmacology at the Feinberg School of Medicine at Northwestern University, where he also served as the Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence from September 2009 to September 2016. During his tenure at Northwestern University, Dr, Mazar served as the Co-chair of the Animal Model Working Group for the NCI Nanotechnology Alliance; was a charter member of the Developmental Therapeutics (DT) study section at the NIH Center for Scientific review; and was a member of the editorial board of Clinical Cancer Research where he continues to serve. Prior to that, Dr. Mazar served as the Chief Scientific Officer at Attenuon, LLC, a private clinical-stage biopharmaceutical company, from February 2000 to July 2009. Dr. Mazar earned his BS in Chemistry from the University of Wisconsin, Parkside and his Ph.D. in Biochemistry from the University of Illinois College of Medicine, Chicago, Illinois.
- Daniel M. Schmitt
Daniel M. Schmitt，自2015年3月起担任Actuate Therapeutics，Inc.首席执行官兼总裁，自2015年4月起担任Actuate Therapeutics，Inc.董事。他此前曾于2009年至2014年担任临床阶段公司Genus Oncology LLC的首席运营官。在此之前，他曾于2004年至2009年担任制药公司Immtech Pharmaceuticals，Inc.的许可和商业开发高级副总裁；于2001年至2004年担任基因组技术公司First Genetic Trust的学术和政府机构市场总经理；此前曾在制药公司G.D. Searle Inc.、制药公司ILEX Oncology，Inc.、制药公司Fujisawa USA，Inc.和制药公司Burroughs Wellcome Co.任职。Schmitt先生还曾于1984年担任国家癌症研究基金会附属研究职位，并于1987年至1988年担任北卡罗来纳大学医学院附属研究职位。他还曾于2014年担任西北大学驻校企业家，并于2011年至2014年担任芝加哥大学和伊利诺伊大学—芝加哥分校的外部专家顾问。施密特先生也是芝加哥创新导师的创始成员。他获得了西弗吉尼亚大学理论数学专业的MBA和化学学士学位。Schmitt先生由于其制药和生物技术经验，包括其在运营管理、新产品开发和业务发展方面的经验，完全有资格担任董事。
Daniel M. Schmitt,has served as Actuate Therapeutics, Inc. Chief Executive Officer and President since March 2015 and Actuate Therapeutics, Inc. director since April 2015. He previously served as Chief Operating Officer of Genus Oncology LLC, a clinical stage company, from 2009 to 2014. Prior to that, he served as Senior Vice President, Licensing and Commercial Development of Immtech Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2009; General Manager, Academic and Government Institution Markets of First Genetic Trust, a genomic technology company, from 2001 to 2004; and previously held positions with G.D. Searle Inc., a pharmaceutical company, ILEX Oncology, Inc., a pharmaceutical company, Fujisawa USA, Inc., a pharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company. Mr. Schmitt has also held research positions affiliated with the National Foundation for Cancer Research in 1984 and the University of North Carolina School of Medicine from 1987 to 1988. He also served as an Entrepreneur-In-Residence at Northwestern University in 2014 and as an external expert consultant for both the University of Chicago and the University of Illinois—Chicago from 2011 to 2014. Mr. Schmitt is also a founding member of Chicago Innovation Mentors. He earned his MBA and a BS in Chemistry with a concentration in Theoretical Mathematics from West Virginia University.- Daniel M. Schmitt，自2015年3月起担任Actuate Therapeutics，Inc.首席执行官兼总裁，自2015年4月起担任Actuate Therapeutics，Inc.董事。他此前曾于2009年至2014年担任临床阶段公司Genus Oncology LLC的首席运营官。在此之前，他曾于2004年至2009年担任制药公司Immtech Pharmaceuticals，Inc.的许可和商业开发高级副总裁；于2001年至2004年担任基因组技术公司First Genetic Trust的学术和政府机构市场总经理；此前曾在制药公司G.D. Searle Inc.、制药公司ILEX Oncology，Inc.、制药公司Fujisawa USA，Inc.和制药公司Burroughs Wellcome Co.任职。Schmitt先生还曾于1984年担任国家癌症研究基金会附属研究职位，并于1987年至1988年担任北卡罗来纳大学医学院附属研究职位。他还曾于2014年担任西北大学驻校企业家，并于2011年至2014年担任芝加哥大学和伊利诺伊大学—芝加哥分校的外部专家顾问。施密特先生也是芝加哥创新导师的创始成员。他获得了西弗吉尼亚大学理论数学专业的MBA和化学学士学位。Schmitt先生由于其制药和生物技术经验，包括其在运营管理、新产品开发和业务发展方面的经验，完全有资格担任董事。
- Daniel M. Schmitt,has served as Actuate Therapeutics, Inc. Chief Executive Officer and President since March 2015 and Actuate Therapeutics, Inc. director since April 2015. He previously served as Chief Operating Officer of Genus Oncology LLC, a clinical stage company, from 2009 to 2014. Prior to that, he served as Senior Vice President, Licensing and Commercial Development of Immtech Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2009; General Manager, Academic and Government Institution Markets of First Genetic Trust, a genomic technology company, from 2001 to 2004; and previously held positions with G.D. Searle Inc., a pharmaceutical company, ILEX Oncology, Inc., a pharmaceutical company, Fujisawa USA, Inc., a pharmaceutical company, and Burroughs Wellcome Co., a pharmaceutical company. Mr. Schmitt has also held research positions affiliated with the National Foundation for Cancer Research in 1984 and the University of North Carolina School of Medicine from 1987 to 1988. He also served as an Entrepreneur-In-Residence at Northwestern University in 2014 and as an external expert consultant for both the University of Chicago and the University of Illinois—Chicago from 2011 to 2014. Mr. Schmitt is also a founding member of Chicago Innovation Mentors. He earned his MBA and a BS in Chemistry with a concentration in Theoretical Mathematics from West Virginia University.
- Andrew P. Mazar
Andrew P. Mazar，自2022年6月起担任Actuate Therapeutics，Inc.首席运营官，在加入公司之前，于2022年1月至2022年6月担任独立顾问。此前，Mazar博士于2016年9月至2022年4月担任公共临床阶段生物制药公司Monopar Therapeutics，Inc.的联合创始人、首席科学官和董事。Mazar博士还是Tactic Pharma，LLC的创始人和管理成员，在那里他开发了WTX-101/ALXN1840，这是一种他共同发明的用于治疗威尔逊病的药物。WTX-101/ALXN1840于2018年被亚力兄制药以超过8亿美元的价格收购。在加入Monopar之前，Mazar博士是西北大学Feinberg医学院的药理学教授，他还曾在2009年9月至2016年9月期间担任发育治疗和住院企业家中心主任。在西北大学任职期间，Mazar博士担任NCI纳米技术联盟动物模型工作组的联合主席；是美国国立卫生研究院科学审查中心发育治疗学（DT）研究部门的特许成员；并且是他继续任职的《临床癌症研究》编辑委员会的成员。在此之前，Mazar博士曾于2000年2月至2009年7月担任私人临床阶段生物制药公司Attenuon，LLC的首席科学官。Mazar博士在威斯康星大学帕克赛德分校获得化学学士学位，在伊利诺伊州芝加哥的伊利诺伊大学医学院获得生物化学博士学位。
Andrew P. Mazar,has served as Actuate Therapeutics, Inc. Chief Operating Officer since June 2022, and prior to joining the Company, he served as an independent consultant from January 2022 to June 2022. Previously, Dr. Mazar was the Co-Founder, Chief Scientific Officer and a director of Monopar Therapeutics, Inc., a public clinical-stage biopharmaceutical company, from September 2016 to April 2022. Dr. Mazar is also a founder and managing member of Tactic Pharma, LLC, where he developed WTX-101/ALXN1840, a drug he co-invented for the treatment of Wilson's disease. WTX-101/ALXN1840 was acquired by Alexion Pharmaceuticals for more than $800 million in 2018. Prior to Monopar, Dr. Mazar was a Professor of Pharmacology at the Feinberg School of Medicine at Northwestern University, where he also served as the Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence from September 2009 to September 2016. During his tenure at Northwestern University, Dr, Mazar served as the Co-chair of the Animal Model Working Group for the NCI Nanotechnology Alliance; was a charter member of the Developmental Therapeutics (DT) study section at the NIH Center for Scientific review; and was a member of the editorial board of Clinical Cancer Research where he continues to serve. Prior to that, Dr. Mazar served as the Chief Scientific Officer at Attenuon, LLC, a private clinical-stage biopharmaceutical company, from February 2000 to July 2009. Dr. Mazar earned his BS in Chemistry from the University of Wisconsin, Parkside and his Ph.D. in Biochemistry from the University of Illinois College of Medicine, Chicago, Illinois.- Andrew P. Mazar，自2022年6月起担任Actuate Therapeutics，Inc.首席运营官，在加入公司之前，于2022年1月至2022年6月担任独立顾问。此前，Mazar博士于2016年9月至2022年4月担任公共临床阶段生物制药公司Monopar Therapeutics，Inc.的联合创始人、首席科学官和董事。Mazar博士还是Tactic Pharma，LLC的创始人和管理成员，在那里他开发了WTX-101/ALXN1840，这是一种他共同发明的用于治疗威尔逊病的药物。WTX-101/ALXN1840于2018年被亚力兄制药以超过8亿美元的价格收购。在加入Monopar之前，Mazar博士是西北大学Feinberg医学院的药理学教授，他还曾在2009年9月至2016年9月期间担任发育治疗和住院企业家中心主任。在西北大学任职期间，Mazar博士担任NCI纳米技术联盟动物模型工作组的联合主席；是美国国立卫生研究院科学审查中心发育治疗学（DT）研究部门的特许成员；并且是他继续任职的《临床癌症研究》编辑委员会的成员。在此之前，Mazar博士曾于2000年2月至2009年7月担任私人临床阶段生物制药公司Attenuon，LLC的首席科学官。Mazar博士在威斯康星大学帕克赛德分校获得化学学士学位，在伊利诺伊州芝加哥的伊利诺伊大学医学院获得生物化学博士学位。
- Andrew P. Mazar,has served as Actuate Therapeutics, Inc. Chief Operating Officer since June 2022, and prior to joining the Company, he served as an independent consultant from January 2022 to June 2022. Previously, Dr. Mazar was the Co-Founder, Chief Scientific Officer and a director of Monopar Therapeutics, Inc., a public clinical-stage biopharmaceutical company, from September 2016 to April 2022. Dr. Mazar is also a founder and managing member of Tactic Pharma, LLC, where he developed WTX-101/ALXN1840, a drug he co-invented for the treatment of Wilson's disease. WTX-101/ALXN1840 was acquired by Alexion Pharmaceuticals for more than $800 million in 2018. Prior to Monopar, Dr. Mazar was a Professor of Pharmacology at the Feinberg School of Medicine at Northwestern University, where he also served as the Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence from September 2009 to September 2016. During his tenure at Northwestern University, Dr, Mazar served as the Co-chair of the Animal Model Working Group for the NCI Nanotechnology Alliance; was a charter member of the Developmental Therapeutics (DT) study section at the NIH Center for Scientific review; and was a member of the editorial board of Clinical Cancer Research where he continues to serve. Prior to that, Dr. Mazar served as the Chief Scientific Officer at Attenuon, LLC, a private clinical-stage biopharmaceutical company, from February 2000 to July 2009. Dr. Mazar earned his BS in Chemistry from the University of Wisconsin, Parkside and his Ph.D. in Biochemistry from the University of Illinois College of Medicine, Chicago, Illinois.
- Paul Lytle
Paul Lytle，自2024年2月起担任Actuate Therapeutics，Inc.临时首席财务官，自2024年6月起担任Actuate Therapeutics，Inc. 首席财务官。Lytle先生是私营生物制药公司Thendor Therapeutics，LLC的联合创始人，自2023年9月起担任其首席财务官。Lytle先生还是Mosaic ImmunoEngineering，Inc.的联合创始人，该公司是一家公共开发阶段的生物技术公司，自2020年8月起担任该公司董事会成员、执行副总裁、首席财务官。此前，Lytle先生于2018年9月至2019年12月担任Breathe Technologies，Inc.的执行副总裁兼首席财务官，该公司是一家私营医疗器械公司，于2019年8月被Hillrom Holdings，Inc.收购。在此之前，Lytle先生于1997年3月至2018年5月担任Avid Bioservices, Inc.（纳斯达克：CDMO）的首席财务官，该公司是一家上市的生物制剂开发公司，最初专注于开发用于治疗癌症的免疫疗法，同时建立了一家新的生物制剂合同开发和制造组织。Lytle先生在长滩加州州立大学获得商学学士学位，重点是会计学，是一名注册会计师（非在职）。
Paul Lytle,has served as Actuate Therapeutics, Inc. Interim Chief Financial Officer since February 2024, and has served as Actuate Therapeutics, Inc. Chief Financial Officer since June 2024. Mr. Lytle is the Co-Founder of Thendor Therapeutics, LLC, a private biopharmaceutical company, and he has served as its Chief Financial Officer since September 2023. Mr. Lytle is also the Co-Founder of Mosaic ImmunoEngineering, Inc., a public development-stage biotechnology company, and he has served on its board of directors and as its Executive Vice President, Chief Financial Officer since August 2020. Previously, Mr. Lytle served as Executive Vice President, Chief Financial Officer of Breathe Technologies, Inc., a private medical device company acquired by Hillrom Holdings, Inc. in August 2019, from September 2018 to December 2019. Prior to that, Mr. Lytle served as Chief Financial Officer of Avid Bioservices, Inc. (Nasdaq: CDMO), a publicly traded biologics development company initially focused on developing immunotherapies for the treatment of cancer while building a new biologics contract development and manufacturing organization, from March 1997 to May 2018. Mr. Lytle received his B.S. in Business with an emphasis in Accounting from California State University at Long Beach and is a Certified Public Accountant (inactive).- Paul Lytle，自2024年2月起担任Actuate Therapeutics，Inc.临时首席财务官，自2024年6月起担任Actuate Therapeutics，Inc. 首席财务官。Lytle先生是私营生物制药公司Thendor Therapeutics，LLC的联合创始人，自2023年9月起担任其首席财务官。Lytle先生还是Mosaic ImmunoEngineering，Inc.的联合创始人，该公司是一家公共开发阶段的生物技术公司，自2020年8月起担任该公司董事会成员、执行副总裁、首席财务官。此前，Lytle先生于2018年9月至2019年12月担任Breathe Technologies，Inc.的执行副总裁兼首席财务官，该公司是一家私营医疗器械公司，于2019年8月被Hillrom Holdings，Inc.收购。在此之前，Lytle先生于1997年3月至2018年5月担任Avid Bioservices, Inc.（纳斯达克：CDMO）的首席财务官，该公司是一家上市的生物制剂开发公司，最初专注于开发用于治疗癌症的免疫疗法，同时建立了一家新的生物制剂合同开发和制造组织。Lytle先生在长滩加州州立大学获得商学学士学位，重点是会计学，是一名注册会计师（非在职）。
- Paul Lytle,has served as Actuate Therapeutics, Inc. Interim Chief Financial Officer since February 2024, and has served as Actuate Therapeutics, Inc. Chief Financial Officer since June 2024. Mr. Lytle is the Co-Founder of Thendor Therapeutics, LLC, a private biopharmaceutical company, and he has served as its Chief Financial Officer since September 2023. Mr. Lytle is also the Co-Founder of Mosaic ImmunoEngineering, Inc., a public development-stage biotechnology company, and he has served on its board of directors and as its Executive Vice President, Chief Financial Officer since August 2020. Previously, Mr. Lytle served as Executive Vice President, Chief Financial Officer of Breathe Technologies, Inc., a private medical device company acquired by Hillrom Holdings, Inc. in August 2019, from September 2018 to December 2019. Prior to that, Mr. Lytle served as Chief Financial Officer of Avid Bioservices, Inc. (Nasdaq: CDMO), a publicly traded biologics development company initially focused on developing immunotherapies for the treatment of cancer while building a new biologics contract development and manufacturing organization, from March 1997 to May 2018. Mr. Lytle received his B.S. in Business with an emphasis in Accounting from California State University at Long Beach and is a Certified Public Accountant (inactive).